Chiesi Orphan

Chiesi Global Rare Diseases is a specialized business unit of the Chiesi Group, a family-owned international pharmaceutical company based in Italy. Established in 2020 and headquartered in Boston, the unit is dedicated to developing and commercializing therapies for rare and ultra-rare diseases with high unmet medical needs. Its portfolio includes treatments for lysosomal storage disorders, such as Elfabrio for Fabry disease and Lamzede for alpha-mannosidosis, as well as therapies for metabolic and hematologic conditions. The company significantly expanded its rare disease pipeline and global reach through the $1.48 billion acquisition of Amryt Pharma in 2023. Chiesi is notable for being the largest pharmaceutical group to achieve B Corp certification, reflecting its commitment to social and environmental standards. The unit continues to invest in diverse modalities, including enzyme replacement therapies and small molecules, to support the rare disease community.